Evidence map›Paper›PMID 22617356›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012

Yohimbine depresses excitatory transmission in BNST and impairs extinction of cocaine place preference through orexin-dependent, norepinephrine-independent processes.

Kelly L Conrad, Adeola R Davis, Yuval Silberman, Douglas J Sheffler, Angela D Shields, Sam A Saleh, Namita Sen, Heinrich J G Matthies, Jonathan A Javitch, Craig W Lindsley and 1 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. αNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article
  6. Article
  7. Review
  8. Dorsal BNST αThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Article
  9. Review
  10. Article
  11. A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?Current topics in behavioral neurosciences · 2017
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kelly L ConradDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Adeola R Davis
Yuval Silberman
Douglas J Sheffler
Angela D Shields
Sam A Saleh
Namita Sen
Heinrich J G Matthies
Jonathan A Javitch
Craig W Lindsley
Danny G Winder
Vanderbilt University · USColumbia University · US

Funding

Training in Fundamental NeuroscienceT32MH064913 · NIMH · VANDERBILT UNIVERSITY · PI IHRIE, REBECCA A, WINDER, DANNY G. · 2001 to 2022
$7.6M
Program in NeurogenomicsT32MH065215 · NIMH · VANDERBILT UNIVERSITY · PI ROGER J COLBRAN · 2002 to 2026
$6.4M
TRAINING PROGRAM IN ION CHANNEL AND TRANSPORTER BIOLOGYT32NS007491 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENTON, JEROD S. · 2001 to 2020
$4.1M
Alcohol action on extended amygdala glutamate synapsesR37AA019455 · NIAAA · VANDERBILT UNIVERSITY · PI WINDER, DANNY G. · 2015 to 2024
$3.9M
Periadolescent Noradrenergic Regulation in the BNSTR01DA019112 · NIDA · VANDERBILT UNIVERSITY · PI WINDER, DANNY G. · 2004 to 2014
$3.3M
Alcohol action on extended amygdala glutamate synapsesR01AA019455 · NIAAA · VANDERBILT UNIVERSITY · PI WINDER, DANNY G. · 2010 to 2014
$1.8M
Molecular Determinants for the Action of PsychostimulantsK05DA022413 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI JAVITCH, JONATHAN A · 2007 to 2016
$1.3M
NIAAA NIH HHS AA019455NIDA NIH HHS DA019112NIDA NIH HHS K05 DA022413NIDA NIH HHS R01 DA019112NIMH NIH HHS MH065215-08NIMH NIH HHS T32 MH064913NIMH NIH HHS T32 MH065215NINDS NIH HHS NS07491NINDS NIH HHS T32 NS007491
6 · The paper itself

Abstract

The alpha2 adrenergic receptor (α(2)-AR) antagonist yohimbine is a widely used tool for the study of anxiogenesis and stress-induced drug-seeking behavior. We previously demonstrated that yohimbine paradoxically depresses excitatory transmission in the bed nucleus of the stria terminalis (BNST), a region critical to the integration of stress and reward pathways, and produces an impairment of extinction of cocaine-conditioned place preference (cocaine-CPP) independent of α(2)-AR signaling. Recent studies show yohimbine-induced drug-seeking behavior is attenuated by orexin receptor 1 (OX(1)R) antagonists. Moreover, yohimbine-induced cocaine-seeking behavior is BNST-dependent. Here, we investigated yohimbine-orexin interactions. Our results demonstrate yohimbine-induced depression of excitatory transmission in the BNST is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) antagonists, but is (1) blocked by OxR antagonists and (2) absent in brain slices from orexin knockout mice. Although the actions of yohimbine were not mimicked by the norepinephrine transporter blocker reboxetine, they were by exogenously applied orexin A. We find that, as with yohimbine, orexin A depression of excitatory transmission in BNST is OX(1)R-dependent. Finally, we find these ex vivo effects are paralleled in vivo, as yohimbine-induced impairment of cocaine-CPP extinction is blocked by a systemically administered OX(1)R antagonist. These data highlight a new mechanism for orexin on excitatory anxiety circuits and demonstrate that some of the actions of yohimbine may be directly dependent upon orexin signaling and independent of norepinephrine and CRF in the BNST.

Indexed as

Adrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AntagonistsAnimalsBehavior, AnimalCocaineCRF Receptor, Type 1Drug-Seeking BehaviorExtinction, PsychologicalIntracellular Signaling Peptides and ProteinsMaleMiceMice, Inbred C57BLMice, KnockoutMorpholinesNeuropeptidesNeurotransmitter AgentsAdra2a protein, mouseAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AntagonistsCocaineCRF Receptor, Type 1Hcrtr1 protein, mouseIntracellular Signaling Peptides and ProteinsMorpholinesNeuropeptidesNeurotransmitter AgentsNorepinephrineNorepinephrine Plasma Membrane Transport ProteinsOrexin ReceptorsOrexinsReboxetineReceptors, Adrenergic, alpha-2Receptors, Corticotropin-Releasing HormoneReceptors, NeuropeptideSlc6a2 protein, mouseYohimbine

Identifiers

PMID22617356
PMCPMC3422490
OpenAlexW1976886359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.